logo

KDNY(Delisted)

Chinook TherapeuticsยทNASDAQ
--
--(--)

KDNY Profile

Chinook Therapeutics, Inc.

A clinical-stage biopharmaceutical company that developing medicines for chronic kidney diseases

--
--
04/15/2015
NASDAQ Stock Exchange
214
12-31
Common stock
400 Fairview Avenue North, Suite 900, Seattle, WA, 98109
--
Chinook Therapeutics, Inc., is a clinical-stage biotechnology company that develops precision medicines for kidney disease. The company's product candidates are investigating rare, serious chronic kidney disease opportunities with a clear clinical pathway. The Company's main project is Atlasentan, an investigational phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases.